CA2076035A1 - Antigenic proteins of plasmodium - Google Patents

Antigenic proteins of plasmodium

Info

Publication number: CA2076035A1
Authority: CA; Canada
Prior art keywords: protein; dna fragment; plasmodium; merozoite; simian
Prior art date: 1990-02-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002076035A

Other languages

English (en)

French (fr)

Inventor

Andrew P. Waters

Thomas F. Mccutchan

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

United States Department of Commerce

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-02-22

Filing date

1991-02-20

Publication date

1991-08-23

1991-02-20 Application filed by Individual filed Critical Individual

1991-08-23 Publication of CA2076035A1 publication Critical patent/CA2076035A1/en

Status Abandoned legal-status Critical Current

Links

241000224016 Plasmodium Species 0.000 title claims abstract description 22
108090000623 proteins and genes Proteins 0.000 title claims description 79
102000004169 proteins and genes Human genes 0.000 title claims description 64
230000000890 antigenic effect Effects 0.000 title claims description 7
210000003936 merozoite Anatomy 0.000 claims abstract description 39
210000004027 cell Anatomy 0.000 claims abstract description 22
241000894007 species Species 0.000 claims abstract description 15
108020004511 Recombinant DNA Proteins 0.000 claims abstract description 13
241001465754 Metazoa Species 0.000 claims abstract description 6
241000223801 Plasmodium knowlesi Species 0.000 claims description 59
239000012634 fragment Substances 0.000 claims description 27
108020004414 DNA Proteins 0.000 claims description 26
241000223810 Plasmodium vivax Species 0.000 claims description 24
210000003743 erythrocyte Anatomy 0.000 claims description 16
230000009545 invasion Effects 0.000 claims description 15
239000013598 vector Substances 0.000 claims description 15
102000053602 DNA Human genes 0.000 claims description 11
238000000034 method Methods 0.000 claims description 8
239000000203 mixture Substances 0.000 claims description 8
239000002671 adjuvant Substances 0.000 claims description 5
238000012258 culturing Methods 0.000 claims description 3
230000008569 process Effects 0.000 claims description 3
239000007787 solid Substances 0.000 claims description 3
229940037003 alum Drugs 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 5
102000007056 Recombinant Fusion Proteins Human genes 0.000 claims 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 claims 1
239000013603 viral vector Substances 0.000 claims 1
102000036639 antigens Human genes 0.000 abstract description 18
108091007433 antigens Proteins 0.000 abstract description 18
108091028043 Nucleic acid sequence Proteins 0.000 abstract description 13
229960005486 vaccine Drugs 0.000 abstract description 9
208000015181 infectious disease Diseases 0.000 abstract description 8
235000018102 proteins Nutrition 0.000 description 47
244000045947 parasite Species 0.000 description 18
210000002966 serum Anatomy 0.000 description 15
101150078331 ama-1 gene Proteins 0.000 description 13
201000004792 malaria Diseases 0.000 description 12
210000001563 schizont Anatomy 0.000 description 12
241000283973 Oryctolagus cuniculus Species 0.000 description 10
241000223960 Plasmodium falciparum Species 0.000 description 8
150000001413 amino acids Chemical class 0.000 description 8
239000002299 complementary DNA Substances 0.000 description 8
238000009826 distribution Methods 0.000 description 8
235000001014 amino acid Nutrition 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
239000000284 extract Substances 0.000 description 5
238000010166 immunofluorescence Methods 0.000 description 5
150000002500 ions Chemical class 0.000 description 5
230000001681 protective effect Effects 0.000 description 5
239000000427 antigen Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
238000010186 staining Methods 0.000 description 4
238000013519 translation Methods 0.000 description 4
238000001262 western blot Methods 0.000 description 4
241000255925 Diptera Species 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
206010035500 Plasmodium falciparum infection Diseases 0.000 description 3
241000700618 Vaccinia virus Species 0.000 description 3
230000009172 bursting Effects 0.000 description 3
238000009396 hybridization Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
239000000047 product Substances 0.000 description 3
210000003046 sporozoite Anatomy 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
XINQFOMFQFGGCQ-UHFFFAOYSA-L (2-dodecoxy-2-oxoethyl)-[6-[(2-dodecoxy-2-oxoethyl)-dimethylazaniumyl]hexyl]-dimethylazanium;dichloride Chemical compound [Cl-].[Cl-].CCCCCCCCCCCCOC(=O)C[N+](C)(C)CCCCCC[N+](C)(C)CC(=O)OCCCCCCCCCCCC XINQFOMFQFGGCQ-UHFFFAOYSA-L 0.000 description 2
101710203310 Apical membrane antigen 1 Proteins 0.000 description 2
101800001415 Bri23 peptide Proteins 0.000 description 2
101800000655 C-terminal peptide Proteins 0.000 description 2
102400000107 C-terminal peptide Human genes 0.000 description 2
241000282412 Homo Species 0.000 description 2
108700026244 Open Reading Frames Proteins 0.000 description 2
241000224017 Plasmodium berghei Species 0.000 description 2
241000223819 Plasmodium fragile Species 0.000 description 2
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000000306 component Substances 0.000 description 2
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
238000011161 development Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000036039 immunity Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
238000013508 migration Methods 0.000 description 2
230000005012 migration Effects 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
210000003463 organelle Anatomy 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000005180 public health Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
229940125575 vaccine candidate Drugs 0.000 description 2
MRXDGVXSWIXTQL-HYHFHBMOSA-N (2s)-2-[[(1s)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2s)-4-methyl-1-oxo-1-[[(2s)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid Chemical compound C([C@H](NC(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C=O)C1NC(N)=NCC1)C(O)=O)C1=CC=CC=C1 MRXDGVXSWIXTQL-HYHFHBMOSA-N 0.000 description 1
NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
241000223836 Babesia Species 0.000 description 1
OLVPQBGMUGIKIW-UHFFFAOYSA-N Chymostatin Natural products C=1C=CC=CC=1CC(C=O)NC(=O)C(C(C)CC)NC(=O)C(C1NC(N)=NCC1)NC(=O)NC(C(O)=O)CC1=CC=CC=C1 OLVPQBGMUGIKIW-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
101150045762 PK66 gene Proteins 0.000 description 1
241000509430 Plasmodium inui Species 0.000 description 1
241001505293 Plasmodium ovale Species 0.000 description 1
206010035502 Plasmodium ovale infection Diseases 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
241000223996 Toxoplasma Species 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
230000009102 absorption Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
244000000054 animal parasite Species 0.000 description 1
239000003430 antimalarial agent Substances 0.000 description 1
238000003556 assay Methods 0.000 description 1
201000008680 babesiosis Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
108010086192 chymostatin Proteins 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
239000000834 fixative Substances 0.000 description 1
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
229960002143 fluorescein Drugs 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
239000008187 granular material Substances 0.000 description 1
231100000206 health hazard Toxicity 0.000 description 1
244000000011 human parasite Species 0.000 description 1
244000052637 human pathogen Species 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
244000000056 intracellular parasite Species 0.000 description 1
238000002372 labelling Methods 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
210000004738 parenchymal cell Anatomy 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
235000020030 perry Nutrition 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
230000002516 postimmunization Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000004321 preservation Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
235000013930 proline Nutrition 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
230000007017 scission Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000012800 visualization Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Biochemistry (AREA)
Toxicology (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Tropical Medicine & Parasitology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

CA002076035A 1990-02-22 1991-02-20 Antigenic proteins of plasmodium Abandoned CA2076035A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US48351690A	1990-02-22	1990-02-22
US483,516		1990-02-22

Publications (1)

Publication Number	Publication Date
CA2076035A1 true CA2076035A1 (en)	1991-08-23

Family

ID=23920376

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002076035A Abandoned CA2076035A1 (en)	1990-02-22	1991-02-20	Antigenic proteins of plasmodium

Country Status (4)

Country	Link
EP (1)	EP0516721A4 (de)
JP (1)	JPH05501112A (de)
CA (1)	CA2076035A1 (de)
WO (1)	WO1991013161A1 (de)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4707357A (en) *	1984-06-26	1987-11-17	The United States Of America As Represented By The Secretary Of The Army	Immunologically active peptides capable of inducing immunization against malaria and genes encoding therefor
WO1990011772A1 (en) *	1989-04-05	1990-10-18	New York University	Merozoite antigens localized at the apical end of the parasite

1991
- 1991-02-20 JP JP3505116A patent/JPH05501112A/ja active Pending
- 1991-02-20 CA CA002076035A patent/CA2076035A1/en not_active Abandoned
- 1991-02-20 EP EP19910905182 patent/EP0516721A4/en not_active Withdrawn
- 1991-02-20 WO PCT/US1991/001059 patent/WO1991013161A1/en not_active Ceased

Also Published As

Publication number	Publication date
EP0516721A1 (de)	1992-12-09
AU7447191A (en)	1991-09-18
EP0516721A4 (en)	1993-02-17
WO1991013161A1 (en)	1991-09-05
AU646662B2 (en)	1994-03-03
JPH05501112A (ja)	1993-03-04

Legal Events

Date	Code	Title	Description
1992-08-18	EEER	Examination request
1996-08-20	FZDE	Discontinued

Publication	Publication Date	Title
Barnes et al.	1998	A novel multi-domain mucin-like glycoprotein of Cryptosporidium parvum mediates invasion
Holder	1988	The precursor to major merozoite surface antigens: structure and role in immunity
Daly et al.	1993	A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice
Tam et al.	1990	Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria.
US7696308B2 (en)	2010-04-13	Recombinant protein containing a C-terminal fragment of Plasmodium MSP-1
US5589343A (en)	1996-12-31	Antibodies which bind to molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a liver stage antigen produced by P. falciparum in hepatocytes
Hines et al.	1995	Genetic and antigenic characterization of Babesia bovis merozoite spherical body protein Bb-1
US20030161838A1 (en)	2003-08-28	Isolation and purification of P. falciparum merozoite protein-142 vaccine
US6669945B1 (en)	2003-12-30	Universal T-cell epitopes for anti-malarial vaccines
CN1741815B (zh)	2010-05-26	疟疾疫苗
Fox et al.	1997	Plasmodium falciparum: an epitope within a highly conserved region of the 47-kDa amino-terminal domain of the serine repeat antigen is a target of parasite-inhibitory antibodies
Daugherty et al.	1997	Baculovirus-mediated expression of Plasmodium falciparum erythrocyte binding antigen 175 polypeptides and their recognition by human antibodies
EP1141305B1 (de)	2006-05-24	Chimärisches gen, dass für die antigenischen determinanten von vier protein aus l. infantum kodiert
JP2000506381A (ja)	2000-05-30	マラリア原虫ｍｓｐ―１のｃ末端断片を含む組換えタンパク質
US5198535A (en)	1993-03-30	Protective malaria sporozoite surface protein immunogen and gene
Locher et al.	1993	Reduction of disulfide bonds in Plasmodium falciparum gp195 abolishes the production of growth-inhibitory antibodies
AU646662C (en)	1994-10-20	Antigenic proteins of plasmodium
AU646662B2 (en)	1994-03-03	Antigenic proteins of plasmodium
Ramasamy et al.	1995	Antibody and clinical responses in volunteers to immunization with malaria peptide–diphtheria toxoid conjugates
James	1989	Application of exoantigens of Babesia and Plasmodium in vaccine development
Ahlborg et al.	1996	Immune responses in congenic mice to multiple antigen peptides based on defined epitopes from the malaria antigen Pf332
US5543323A (en)	1996-08-06	Plasmodium merozoite rhoptries antigenic polypeptides
EP0433378B1 (de)	1995-10-25	Allelische varianten von -i(plasmodium falciparum) merozoit-oberflächen-antigen
US20030161839A1 (en)	2003-08-28	Recombinant P. falciparum merozoite protein-142 vaccine
Kironde et al.	1991	Towards the design of heterovalent anti-malaria vaccines: a hybrid immunogen capable of eliciting immune responses to epitopes of circumsporozoite antigens from two different species of the malaria parasite, Plasmodium